
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is positioned for success in the biopharmaceutical industry due to its innovative T-cell programming technologies and a strong clinical-stage pipeline with multiple treatments in development for various cancers. The company's financials are also showing improvement with a lower COGS in the first quarter and expected operating expense reductions due to a cost restructuring plan. The company's potential for earlier treatment and inclusion in NCCN guidelines, as well as its perceived safety and success in clinical trials, are positive indicators for future growth and success.
Bears say
Autolus Therapeutics is facing potential challenges with reimbursement and production capabilities for its CAR-T therapies, limiting the market potential of its flagship product Aucatzyl. Furthermore, the positive data from the frontline IST may not result in immediate market expansion due to changes in NCCN guidelines not expected until 2027. Combined, these factors suggest a potential struggle for Autolus in achieving significant revenue growth in the near future.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares